Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. - Wikidata - awgldk - TriplyDB

Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.

Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.

http://www.wikidata.org/entity/Q44807745

about

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.Voriconazole in the management of nosocomial invasive fungal infections.Supportive care in patients with acute leukaemia: historical perspectives.Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital.Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients.Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.Prophylactic antifungal agents used after lung transplantation.Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review Treatment principles for the management of mold infections.Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: "real life" evaluation.Granulocyte transfusion therapy: randomization after all?Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis.Invasive aspergillosis and allogeneic hematopoietic stem cell transplantation in children: a 15-year experience.Invasive coinfection with Aspergillus and Mucor in a patient with acute myeloid leukemia.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

P2860

Q28388806-E09139E2-A9EA-4514-BDE4-0D05C212964F Q34166590-15D27733-2E1D-46F5-BAC2-EB21C76BD427 Q34532546-CC728485-9168-4AE5-86AA-0E4E230C759D Q34756973-1053E517-5A4E-4713-9A34-2D8A50FBA7F1 Q35166823-E2B459A7-FED3-4B17-996A-F83E6D88E8BD Q35265135-DF15E608-4753-4E5D-92CB-D2944CA18BAD Q35687657-D8263DDC-F719-491A-B95D-EBC3F347D338 Q35821259-8FE1FCD8-A00A-4DCD-B507-43DE09269A85 Q36046991-F21AE641-39CF-49CC-B8F3-4CFAF0191FD1 Q36505508-C392CE19-35E5-41D2-A389-92D1BAA31E6F Q36867435-9FDAD2C7-B4DD-44B2-86E2-B7B726304D20 Q37150434-BEC0292E-93C8-4EA9-B1FC-3EE64E61A1B8 Q37442798-CD9CEEA3-5924-4A8F-B676-E80A1BB49F14 Q37697380-895F663E-9736-4FB2-BB30-6E85A9259FF2 Q37935599-117EFF2A-5B6D-4856-A144-0E3E4E47EEAB Q37993110-D9DA8CD6-F172-4215-9E28-1A1EA478B276 Q38111391-75B3BB47-6FEA-4A7F-B925-8EEA6B9245D0 Q38265845-6DC39A0D-129E-4EF1-887E-DF72DE9E06A3 Q40360694-D3278A07-C1D6-4CC3-B6A5-CF930EB4884A Q40886644-7B5087F0-F19C-4E7F-B1A4-1358FD781734 Q42956275-7DC2F748-15C5-4B65-84C4-BF926A1082C0 Q42970799-4E5480B8-A104-4185-B5B6-3CC8FE2B5F20 Q44558731-B868DCF1-A704-4252-8C4B-BC9B630C8D2C Q45757964-197149EC-3FC4-458E-AD0B-42E51CD464F6 Q46709631-B2F687E0-DB66-4458-9AAF-3D357F5329D5 Q51169948-1CA2628A-7313-4E20-A313-A38AA8A88890 Q51617424-3251AC17-A09B-4575-BD93-F4DDDC9D5205

P2860

Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.

http://www.wikidata.org/entity/Q44807745

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Secondary antifungal prophylax ...... em cell transplant recipients.

@en

Secondary antifungal prophylax ...... em cell transplant recipients.

@nl

type

label

Secondary antifungal prophylax ...... em cell transplant recipients.

@en

Secondary antifungal prophylax ...... em cell transplant recipients.

@nl

prefLabel

Secondary antifungal prophylax ...... em cell transplant recipients.

@en

Secondary antifungal prophylax ...... em cell transplant recipients.

@nl

P1433

Q44807745-312BC70D-07AF-4A03-B42F-8D66542A2B94

P1476

Q44807745-F3E48637-053A-40B3-921B-24BFFFB28DFF

P2093

Q44807745-1339CD75-6F58-423D-B641-C19DE11F2F44

Q44807745-154D985B-603E-4F38-B3AF-7CE31FAE3A0B

Q44807745-1D5C23DF-CE07-4F3F-A926-DEF442812F4B

Q44807745-412C0AF1-580C-40D7-A802-7EBE1FDEB9CE

Q44807745-556CC3AE-D265-4764-A14D-A8A4168157EB

Q44807745-68DA7638-D8BD-4D8D-87B9-E2CF388517A0

Q44807745-910209BC-43EB-4915-B5E2-A223E1876D90

Q44807745-AFD0F657-5A18-4AA6-81CC-58CC8E84DD01

P2860

Q44807745-1810C0F6-3028-434F-8824-935200155268

Q44807745-2829A737-9335-4A48-A4B6-C29BD879142A

Q44807745-2F6A5E80-6259-4655-9E51-733167E4C7AC

Q44807745-3F8DF3F5-A91E-436B-A4B0-F9B8820D0A3A

Q44807745-4AA982EC-4878-47F1-B31B-58605D73B1BB

Q44807745-554C3BF3-C387-4112-99B9-19703E1E6674

Q44807745-6748E151-40E2-4743-8D20-37A312DBE354

Q44807745-7E2EC85E-B4E9-4B34-A032-A8149CC676E6

Q44807745-909A4F92-4F8F-4476-90EB-DCDE32074AB5

Q44807745-9D60317B-E2AF-4AE6-94B8-1E53976EC5D8

P2888

Q44807745-F6669DBF-2E84-4D51-9FC9-695F106C596E

P304

Q44807745-1BE15076-7477-46D6-953D-B22FE93AAD28

P31

Q44807745-F3B40C88-381D-496B-B2AE-A75ED4AC8DD1

P356

Q44807745-719F2C35-7F52-4EBE-8819-2240E66D198B

P407

Q44807745-69E64FDC-9290-49CF-A046-870EFE5420EB

P433

Q44807745-F9D03765-074B-496C-BF12-4EBE5E02462A

P478

Q44807745-6C1AB8FF-7A5F-4F55-AB86-A0291CC7E307

P50

Q44807745-C48E5A66-ABEB-45FC-9C43-B4CEC18E0266

P577

Q44807745-1F9BDC11-1EF5-49EC-8C66-37CC0EB9E5E8

P5875

Q44807745-DFA1C87B-0E26-4716-8C69-2140175B6105

P6179

Q44807745-BF3DD484-B03E-4C82-94A9-A73C6D05687D

P698

Q44807745-8809B349-8911-48CF-A064-3459FD637274

P921

Q44807745-5D27B116-F4D6-4FDA-BB1F-27D20C7FCE33

P356

P1433

Bone Marrow Transplantation

P1476

Secondary antifungal prophylax ...... em cell transplant recipients.

@en

P2093

Bastié JN

http://www.w3.org/2001/XMLSchema#string

Castaigne S

http://www.w3.org/2001/XMLSchema#string

Chehata S

http://www.w3.org/2001/XMLSchema#string

Cordonnier C

http://www.w3.org/2001/XMLSchema#string

Kuentz M

http://www.w3.org/2001/XMLSchema#string

Maury S

http://www.w3.org/2001/XMLSchema#string

Pautas C

http://www.w3.org/2001/XMLSchema#string

Ribaud P

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Aspergillosis case-fatality rate: systematic review of the literature.

Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution.

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Voriconazole: a new triazole antifungal agent.

Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study.

Hepatosplenic candidiasis: successful treatment with fluconazole.

Chemoprophylaxis for pulmonary aspergillosis during intensive chemotherapy.

Cyclophosphamide metabolism is affected by azole antifungals.

Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions.

P2888

P304

943-948

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1704469

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Stéphane Bretagne

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8666138

http://www.w3.org/2001/XMLSchema#string

P6179

1002235220

http://www.w3.org/2001/XMLSchema#string

P698

15034546

http://www.w3.org/2001/XMLSchema#string

P921